Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TY-302 plus abiraterone in metastatic castration-resistant prostate cancer after failure of prior novel endocrine therapy
CTR20252941Phase 2Active
- Sponsor
- TYK Medicines
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ty-302 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by TYK Medicines. Primary endpoints: Safety and dose-escalation outcomes and Radiographic progression-free survival. Started Jul 2025; status: active.
02
Drugs
ty-302
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20252941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252941.